EP1109020B1 - Method for screening candidate compounds for antitumor drug - Google Patents
Method for screening candidate compounds for antitumor drug Download PDFInfo
- Publication number
- EP1109020B1 EP1109020B1 EP99938521A EP99938521A EP1109020B1 EP 1109020 B1 EP1109020 B1 EP 1109020B1 EP 99938521 A EP99938521 A EP 99938521A EP 99938521 A EP99938521 A EP 99938521A EP 1109020 B1 EP1109020 B1 EP 1109020B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- cells
- flt3
- itd
- blood
- candidate compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57426—Specifically defined cancers leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
Definitions
- the present invention relates to a method for screening a candidate compound for a drug against tumors, in particular, blood cancers. More specifically, it relates to a method for screening a compound that inhibits the function of FLT3/ITD in animal cells, including blood cell lines.
- FLT3 is a protein of a class III receptor tyrosine kinase (RTK), and is presumed to be involved in the hematopoietic system ( Rosnet, O. et al., 1991, Genomics 9:380-385 ; Rosnet, O. et al., 1991, Oncogene, 6:1641-1650 ; Matthews, W. et al., 1991, Cell, 65: 1143-1152 ; Rosnet, O. et al., 1993, Blood, 82: 1110-1119 ).
- RTK receptor tyrosine kinase
- RTK has an extracellular region containing five immunoglobulin-like domains, one juxtamembrane region (JM domain), two tyrosine domains (TK1 and TK2) intervened by a kinase insert domain (KI domain), and the C-terminal domain.
- FLT3 is strongly expressed in the hematopoietic stem cells as well as the brain, placenta and liver ( Rosnet, O. et al., 1991, Oncogene 6:1641-1650 ; Matthews, W. et al., 1991, Cell, 65: 1143-1152 ; Rosnet, O.
- a ligand for FLT3 FL is expressed from stromal cells in the bone marrow, and present in a membrane-bound or soluble form. This ligand stimulates stem cells independently or together with other cytokines ( Hannum, C. et al., 1994, Nature, 368: 643-648 ; McKenna, H. J. et al., 1995, Blood, 86: 3413-3420 ; Hirayama, F., 1995, Blood, 85: 1762-1768 ; Lisovsky, M. et al., 1996, Leukemia, 10: 1012-1018 ). Therefore, the ligand-receptor interaction between FL and FLT3 is thought to play an important role in the hematopoietic system.
- FLT3 expression is observed in most of the specimens from patients with acute myeloid leukemia (AML) or acute chronic lymphocytic leukemia (ALL). High levels of FLT3 expression are also found in the patients with chronic myeloid leukemia (CML).
- FL is known to stimulate the proliferation of AML cells more prominently than AML cells ( Piacibello, W. et al., 1995, Blood, 86: 4105-4114 ; Stacchini, A. et al., 1996, Leukemia, 10: 1584-1591 ; Lisovsky, M. et al., 1996, Blood, 88: 3987-3997 ; Birg, F.
- FLT3 has a function specific to myeloid cells.
- FLT3 and FL are co-expressed ( DaSilva, N. et al., 1994, Leukemia, 8: 885-888 ; Meierhoff, G. 1995, Leukemia, 9: 1368-1372 ), suggesting their autocrine or paracrine mechanism.
- FLT3 mutations are found in about 20% of AML patients and about 3% of patients with myelodysplasia syndrome (MDS), but not in patients with chronic myeloid leukemia (CML) or lymphocytic blood cancer ( Yokota, S. et al., 1997, Leukemia 11: 1605-1609 ).
- MDS myelodysplasia syndrome
- CML chronic myeloid leukemia
- lymphocytic blood cancer Yokota, S. et al., 1997, Leukemia 11: 1605-1609
- mutant FLT3 genes containing ITD hereinafter referred to as "FLT3/ITD”
- FLT3/ITD mutant FLT3 genes containing ITD
- An objective of the present invention is to elucidate the FLT3/ITD function in blood cancers, such as leukemia, and to provide a screening method for a candidate compound for a drug against tumors, such as blood cancer, using inhibition of the FLT3/ITD function as an index.
- the inventors have investigated the functions of FLT3/ITD in the blood cell lines to find that tyrosine residues present in FLT3/ITD are constitutively phosphorylated in the cell lines tested, that blood cells into which FLT3/ITD is introduced proliferate in an IL-3-independent manner, and that syngeneic mice inoculated with those blood cells develop tumors.
- IL-3-independent cell proliferation is induced by proliferative signaling of FLT3/ITD mediated by tyrosine-phosphorylation of FLT/ITD, and that this proliferation, in particular, is responsible for progression of tumors in hematopoietic organs, such as acute myeloid leukemia.
- inhibition of FLT3/ITD function can be used as an index to screen for a candidate compound for a drug that can be used in the treatment of blood cancers, etc.
- the present invention relates to a method for screening a candidate compound for a drug used in the treatment of tumors, using inhibition of FLT3/ITD function in the blood cells as an index. More specifically, the present invention relates to:
- tyrosine-phosphorylation of FLT/ITD was detected in the myeloid cell line, FDC-P1 (ATCC CRL-12103), into which FLT3/ITD was introduced (Example 3).
- FDC-P1 which proliferates IL-3-dependently
- FDC-P1 cells into which FLT3/ITD was introduced were found to proliferate IL-3-independently (Example 4).
- One embodiment of the present invention is a method for screening a candidate compound for a drug against tumors, such as blood cancers, using as an index inhibition of the proliferation of animal cells, such as blood cells, in which FLT3/ITD is expressed.
- this method comprises the steps of (a) providing animal cells that proliferate cytokine-independently due to the expression of FLT3/ITD, (b) contacting said cells with a test sample and culturing said cells in the absence of cytokines, (c) detecting the proliferation of said cells, and (d) selecting a compound that inhibits said cell proliferation.
- Another embodiment of the present invention is a method for screening a candidate compound for a drug against tumors, such as blood cancers, using as an index inhibition of tyrosine-phosphorylation of FLT3/ITD in blood cells, etc.
- this method comprises the steps of (a) providing animal cells that proliferates cytokine-independently due to expression of FLT3/ITD, (b) contacting said cells with a test sample and culturing said cells in the absence of cytokines, (c) detecting phosphorylation of FLT3/ITD in said cells, and (d) selecting a compound that inhibits the phosphorylation of FLT3/ITD in said cells.
- Yet another embodiment of the present invention is a method for screening a candidate compound for a drug against tumors, such as blood tumors, using as an index differentiation-inducing potency, i.e. an effect that facilitates cell differentiation, of animal cells, such as blood cells, in which FLT3/ITD is expressed.
- this method comprises the steps of (a) providing animal cells in which differentiation-inducing potency is suppressed due to expression of FLT3/ITD, (b) contacting said cells with a candidate compound and culturing said cells, (c) detecting the differentiation-inducing potency of said cells, and (d) selecting a compound that facilitates differentiation of said cells.
- Compounds that facilitate cell differentiation include compounds that stimulate the cell differentiation by themselves or together with other cytokines that are known to stimulate the cell differentiation.
- the tumors targeted by drug candidate compounds screened by the method of the present invention include any tumors that are caused by internal tandem duplication (ITD) of FLT3, inter alia, blood cancers, for example, acute myeloid leukemia and myelodysplasia syndrome.
- ITD internal tandem duplication
- blood cancers for example, acute myeloid leukemia and myelodysplasia syndrome.
- acute myeloid leukemia is the most preferable as a target disease.
- Candidate compounds used in the screening include, but are not limited to, purified proteins (including antibodies), expression products from a gene library, a library of synthetic peptides, cell extracts, cell culture supernatant, a library of synthetic low-molecular-weight compounds, oligonucleotides, etc.
- Any animal cell can be used as the cells used for the screening as long as it proliferates cytokine-independently or has suppressed differentiation-inducing potency due to the FLT3/ITD expression.
- Blood cells (including hematopoietic stem cells) are preferable.
- Such cells include, for example, FDC-P1 cells (ATCC: CRL-12103), 32D cells (RICKEN (The Institute of Physical and Chemical Research) Cell Bank: RCB 1145), Ba/F3 cells (RICKEN Cell Bank: RCB 0805), DA-3 cells (RICKEN Cell Bank: RCB 1144), all of which show IL3-independent cell proliferation.
- FDC-P1, 32D, and Ba/F3 cells are preferable.
- FLT3/ITD Intracellular expression of FLT3/ITD can be carried out by means of a genetic engineering technique well known to those skilled in the art. Any FLT3/ITD can be used for its expression in the cell, as long as it induces the proliferation of blood cells in a cytokine-independent manner.
- FLT3/ITD includes, for example, FLT3/ITD comprising any one of the amino acid sequences of SEQ ID NO: 2, 4, 6 and 8.
- the FLT3/ITD sequences described in the literatures Yokota, S. et al. 1997, Leukemia 11: 1605-1609 ; Kiyoi, H. et al. 1997, Leukemia 11: 1447-1452 ) canbeusedinthisinvention.
- FLT3/ITD newly obtained from patients with blood cancer can also be used.
- FLT3/ITD may be synthesized artificially or derived from cells.
- Candidate compounds can be contacted with cells by the method suitable to the compounds used, for example, by the method in which a candidate compound is added to the cell culture medium or the method in which a candidate compound is introduced into the cells.
- the parent cells are cultured in the presence of IL-3 and a candidate compound is added to the culture to determine the effects of the candidate compound on IL-3-dependent cell-proliferation in parallel with the experiment above.
- the compounds that can be isolated through the screening of the present invention may vary in their activities.
- Examples of the compounds include, for example, those inhibiting the function of FLT3/ITD through the direct action thereon, those indirectly inhibiting the FLT3/ITD function by acting on a molecule that binds to FLT3/ITD or phosphorylated FLT3/ITD (e.g.
- adapter proteins such as SHC, Grb2, Cbl, PI3K, RAS-GAP and PLC- ⁇
- those acting on a group of proteins that is involved in the signal transduction pathway from FLT/ITD up to cell proliferation those acting on a protein that can phosphorylate FLT3/ITD and inhibiting the function thereof, those acting on a group of proteins that is involved in the signal transduction pathway from FLT/ITD to cause its phosphorylation, and those dephosphorylating FTL3/ITD that is constitutively phosphorylated.
- These compounds are candidates for a drug to treat tumors, such as blood cancers, in the development which FLT3/ITD is involved.
- the compounds that specifically inhibit the FLT3/ITD function but not inhibit the function of wild type FLT3 are preferable as candidates for drugs to specifically treat the diseases mentioned above caused by FLT3/ITD.
- a compound in case a compound is isolated by the screening method of the present invention it may be used as a drug.
- the drug may be combined with a pharmaceutically acceptable carrier or medium (e.g. saline, vegetable oil, suspending agent, surfactant, stabilizer, etc.) and administered to patients.
- a pharmaceutically acceptable carrier or medium e.g. saline, vegetable oil, suspending agent, surfactant, stabilizer, etc.
- the drug may be administered via various routes, for example, percutaneously, intranasally, transbronchially, intramuscularly, intravenously, or orally, depending on the properties of the compound. Dosage may vary depending on the factors, such as age, weight, condition of the patient and the administration method, but those skilled in the art can properly determine the suitable dosage.
- aberrant FLT3 refers to any abnormalities of FLT3 including not only expression of mutant to FLT3 but also overexpression of wild type FLT3.
- High molecular weight DNA was isolated from leukemia cells, and a DNA fragment containing the JM domain of the FLT3 protein was amplified by PCR according to the method described in Kiyoi, H., Leukemia 11: 1447-1452, 1997 .
- the bands that differed from the band of the wild-type in size were excised from agarose gel and purified with Qiaex gel extraction kit (Qiagen), followed by cloning into pMOSBlue T vector (Amersham) according to the manufacturer's instruction.
- Ten colonies of the recombinants were cultured on the LB medium, and the plasmid DNA was prepared with QIAprep spin plasmid miniprep kit (QIAGEN).
- Nucleotide sequences of these clones were confirmed by sequencing. Expression of the FLT3 mRNA was confirmed by RT-PCR according to the method described in Kiyoi, H., Leukemia 11: 1447-1452, 1997 . The bands that differed from the band of the wild type in size were cloned according to the method described above, and their nucleotide sequences were confirmed by sequencing.
- Table 1 The results are summarized in Table 1 showing the frequency of FLT3/ITD within various blood cancers (the number of cases in which FLT3/ITD was detected/the total number of cases tested).
- Table 1 Diagnosis Frequency Diagnosis Frequency ALL 0/48 AML(total) 35/221 ATL 0/14 M0 0/2 CLL 0/15 M1 5/18 ET 0/3 M2 4/29 ML 0/16 M3 16/124 MM 0/38 M4 6/24 Histiocytosis 0/1 M5 4/20 CML-BC 0/13 M6 0/1 CMMoL 0/17 M7 0/3 MDS 1/15
- FLT3/ITD is specifically found in AML; its percent frequency was so high as about 20%. FLT3/ITD was also found in MDS, but its percent frequency was so low as about 3%.
- the cDNA synthesized was used as a template to amplify the MunI-EcoRV fragment, which contains the tandem repeat region found in mutants FTL3 cDNA, by RT-PCR.
- MunI-F primer SEQ ID NO: 11/5'-CAACAATTGGTGTTTGTCTCCTCTT-3'
- EcRV-R primer SEQ ID NO: 12/5'-CATGATATCTCGAGCCAATCCAAAG-3'
- the amplified fragments were cleaved with MunI and EcoRV (Boehringer-Mannheim-Yamanouchi), resolved on agarose gel, and purified according to the aforementioned method.
- Expression vector pCDHF3 (a gift from Dr. Olivier Rosnet), which carries a full-length wild type FLT3 cDNA ( Rosnet, O. et al., Blood 82:1110-1119 ; Accession No. S64785), was cleaved with MunI and EcoRV, and the purified FLT3/ITD fragment was inserted into the vector.
- Four mutants of FLT3/ITD (Mtl, Mt2, Mt3 and Mt4) were used.
- Nucleotide sequences of the mutated regions of Mt1 to Mt4 are shown as SEQ ID NOs. 1, 3, 5 and 7, and their amino acid sequences are shown as SEQ ID NOs. 2, 4, 6 and 8, respectively.
- Expression vectors for Mt1 to Mt4 were transfected into the blood cells.
- FLT3/ITD expression plasmids thus obtained were introduced into blood cells as follows.
- the cells were co-transfected with a 10:1 mixture of any one of the expression plasmids and pBabe-neo vector ( Nucleic Acids Res., 18:3587-3596, 1990 ) by using Bio-Rad Gene Pulser Cuvettes (Bio-Rad; 300 V, 960 ⁇ F), and selected with 800 ng/ml neomycin.
- FLT3 expressions of the cloned cells were verified by FACS and Western blotting to establish the transfected clones.
- FLT3/ITD genes were introduced into a myeloid cell line, FDC-P1 cells.
- the transfectants were cultured in RPMI 1640 medium supplemented with 10% FCS (GIBCO), and then centrifuged at 1000 rpm for 5 minutes to recover 2 x 10 7 cells.
- the cell pellets were washed with PBS, dissolved in lysis buffer (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 2 mM EDTA, Nonidet P-40, 50 mM NaF, 10 mg/ml aprotinin, 10 mg/ml leupeptin, 1 mM Na 3 VO 4 , 50 mM Na 2 MoO 4 , 1 mM phenylmethylsulfonyl fluoride (PMSF)), allowed to stand for 1 hour at 4°C, then centrifuged at 15000 rpm for 30 minutes.
- lysis buffer (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 2 mM EDTA, Nonidet P-40, 50 mM NaF, 10
- Fig. 1 The results for FDC-P1 cells are shown in Fig. 1 .
- all the FLT3/ITDs introduced into FDC-P1 cells were phosophorylated at the tyrosine residues, indicating that a signaling pathway for tyrosine-phosphorylation of FLT3/ITD is constitutively activated.
- wild type FLT3 protein was not phosphorylated in the absence of FL.
- FDC-P1 cells (5 x 10 4 cells) into which wild type FLT3 (wt) or FLT3/ITD (Mt1 to Mt4) was introduced were cultured in the four media indicated below on a 24-well plate at 37°C in a CO 2 incubator.
- the cells were stained with trypan blue and the viable cells were counted at 24-hour intervals for 4 days to determine the proliferation potency of each cell line.
- the results are shown in Fig. 2 .
- the cells into which wild type FLT3 is introduced were not able to proliferate in the absence of IL-3, and this IL-3 dependency did not alter even after FL, a ligand for FLT3, was added to the medium. Also, synergistic effect of IL-3 and FL was not observed.
- neither proliferation promoting effect nor synergistic effect of IL-3 and FL were found in these cells.
- the present invention provides a method for screening candidate compounds for drug against tumors, such as blood cancers, using inhibition of FLT3/ITD function as an index.
- Compounds to be isolated by the method of the present invention could have an inhibitory effect on aberrant proliferation of cells, such as blood cells, caused by FLT3/ITD expression found in blood cancers, in particular, acute myeloid leukemia, and can thus be utilized for development of pharmaceuticals for these diseases.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hospice & Palliative Care (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
- The present invention relates to a method for screening a candidate compound for a drug against tumors, in particular, blood cancers. More specifically, it relates to a method for screening a compound that inhibits the function of FLT3/ITD in animal cells, including blood cell lines.
- FLT3, as well as KIT, FMS and PDGFR, is a protein of a class III receptor tyrosine kinase (RTK), and is presumed to be involved in the hematopoietic system (Rosnet, O. et al., 1991, Genomics 9:380-385; Rosnet, O. et al., 1991, Oncogene, 6:1641-1650; Matthews, W. et al., 1991, Cell, 65: 1143-1152; Rosnet, O. et al., 1993, Blood, 82: 1110-1119). Structurally, RTK has an extracellular region containing five immunoglobulin-like domains, one juxtamembrane region (JM domain), two tyrosine domains (TK1 and TK2) intervened by a kinase insert domain (KI domain), and the C-terminal domain. FLT3 is strongly expressed in the hematopoietic stem cells as well as the brain, placenta and liver (Rosnet, O. et al., 1991, Oncogene 6:1641-1650; Matthews, W. et al., 1991, Cell, 65: 1143-1152; Rosnet, O. et al., 1993, Blood, 82: 1110-1119; Rusten, L.S., 1996, 87: 1317-1325). A ligand for FLT3 (FL) is expressed from stromal cells in the bone marrow, and present in a membrane-bound or soluble form. This ligand stimulates stem cells independently or together with other cytokines (Hannum, C. et al., 1994, Nature, 368: 643-648; McKenna, H. J. et al., 1995, Blood, 86: 3413-3420; Hirayama, F., 1995, Blood, 85: 1762-1768; Lisovsky, M. et al., 1996, Leukemia, 10: 1012-1018). Therefore, the ligand-receptor interaction between FL and FLT3 is thought to play an important role in the hematopoietic system.
- On the other hand, high levels of FLT3 expression are observed in most of the specimens from patients with acute myeloid leukemia (AML) or acute chronic lymphocytic leukemia (ALL). High levels of FLT3 expression are also found in the patients with chronic myeloid leukemia (CML). FL is known to stimulate the proliferation of AML cells more prominently than AML cells (Piacibello, W. et al., 1995, Blood, 86: 4105-4114; Stacchini, A. et al., 1996, Leukemia, 10: 1584-1591; Lisovsky, M. et al., 1996, Blood, 88: 3987-3997; Birg, F. et al., 1992, Blood, 80: 2584-2593, Dehmel, U. et al., 1996, Leukemia, 10: 261-270). This indicates that FLT3 has a function specific to myeloid cells. In several leukemia-lymphoma cell lines, FLT3 and FL are co-expressed (DaSilva, N. et al., 1994, Leukemia, 8: 885-888; Meierhoff, G. 1995, Leukemia, 9: 1368-1372), suggesting their autocrine or paracrine mechanism.
- Mutations in cytokine receptors that occur in the process of tumorigenesis have received attention in recent years. To date, mutations in c-fms and c-kit in human leukemia have been reported (Lowenverg, B. and Touw, I. P., 1993, Blood, 81: 281-292). Murine NIH3T3 cells transfected with a mutant c-fms undergo ligand-independent transformation (Roussel, M. et al., 1988, Cell, 55: 979-988). M-CSF, a ligand for fms, increases cell proliferation only slightly in the most of leukemic patients. Thus, the significance of FMS mutation is still unknown (Lowenberg, B. and Touw, I. P., 1993, Blood, 81: 281-292). KIT and its ligand SCF stimulate proliferation of leukemia and stem cells (Lowenberg, B. and Touw, I. P., 1993, Blood, 81: 281-292; Witte, O., 1990, Cell, 63: 5-6). However, mutations in c-kit gene have been found in the mast cell leukemic cell lines, which mutations have not been fully identified in clinical samples (Tsujimura, T. et al., 1994, Blood, 83: 2619-2626; Kitayama, H., 1996, Blood, 88: 995-1004; Tsujimura, Y. et al., 1996, Blood, 87: 273-283).
- Recently, somatic mutations in FLT3 were found in AML patients (Nakao, M. et al., 1996, Leukemia, 10: 1911-1918). In these mutants, internal tandem duplication (ITD) was found in the region coding for the JM domain of the FLT3 gene. The duplicated sequences predominantly contain exon 11/12 and intron 11, though varying in length in each sample, and they commonly have an extended JM domain which is translatable in a protein due to an extended in-frame open reading frame.
- FLT3 mutations are found in about 20% of AML patients and about 3% of patients with myelodysplasia syndrome (MDS), but not in patients with chronic myeloid leukemia (CML) or lymphocytic blood cancer (Yokota, S. et al., 1997, Leukemia 11: 1605-1609). To the inventors' knowledge, mutant FLT3 genes containing ITD (hereinafter referred to as "FLT3/ITD") are found in some AML patients when the tumor recurs, even though they are not found by the early diagnosis, suggesting that FLT3/ITD is responsible for progression of leukemia. However, the role of FLT3/ITD in the progression of leukemia has not been reported so far.
- An objective of the present invention is to elucidate the FLT3/ITD function in blood cancers, such as leukemia, and to provide a screening method for a candidate compound for a drug against tumors, such as blood cancer, using inhibition of the FLT3/ITD function as an index.
- To solve the problems above, the inventors have investigated the functions of FLT3/ITD in the blood cell lines to find that tyrosine residues present in FLT3/ITD are constitutively phosphorylated in the cell lines tested, that blood cells into which FLT3/ITD is introduced proliferate in an IL-3-independent manner, and that syngeneic mice inoculated with those blood cells develop tumors. These findings suggest that IL-3-independent cell proliferation is induced by proliferative signaling of FLT3/ITD mediated by tyrosine-phosphorylation of FLT/ITD, and that this proliferation, in particular, is responsible for progression of tumors in hematopoietic organs, such as acute myeloid leukemia. Based on these observations, the inventors found that inhibition of FLT3/ITD function can be used as an index to screen for a candidate compound for a drug that can be used in the treatment of blood cancers, etc.
- Specifically, the present invention relates to a method for screening a candidate compound for a drug used in the treatment of tumors, using inhibition of FLT3/ITD function in the blood cells as an index. More specifically, the present invention relates to:
- (1) a method for screening a candidate compound for an antitumor drug, said method comprising the steps of:
- (a) providing animal cells which express FLT3/ITD, whereupon said cells proliferate IL-3 independently;
- (b) contacting said cells with a candidate compound and culturing said cells in the absence of IL-3;
- (c) detecting the proliferation of said cells; and
- (d) selecting the candidate compound that inhibits the proliferation of said cells;
- (2) a method for screening a candidate compound for an antitumor drug, said method comprising the steps of:
- (a) providing animal cells which express FLT3/ITD, whereupon said cells proliferate IL-3 independently;
- (b) contacting said cells with a candidate compound and culturing said cells in the absence of IL-3;
- (c) detecting phosphorylation of FLT3/ITD in said cells; and
- (d) selecting the candidate compound that inhibits the phosphorylation of FLT3/ITD in said cells;
- (3) a method for screening a candidate compound for an antitumor drug, said method comprising the steps of:
- (a) providing animal cells which express FLT3/ITD, whereupon G-CSF-induced differentiation of said cells is suppressed;
- (b) contacting said cells with a candidate compound and culturing said cells in the presence of G-CSF;
- (c) detecting the differentiation-inducing potency of said cells; and
- (d) selecting the candidate compound that facilitates differentiation of said cells;
- (4) the method according to any one of (1) to (3), wherein said tumor is a blood cancer;
- (5) the method according to (4), wherein said blood cancer is acute myeloid leukemia or myelodysplasia syndrome;
- (6) the method according to any one of (1) to (3), wherein said animal cells are animal blood cells;
- (7) the method according to (6), wherein said animal blood cells are FDC-P1, 32D, or a BaF cells, in which FLT3/ITD gene has been introduced to express the FLT3/ITD; and
- (8) the method according to (3), wherein said animal cells are 32D cells, in which the FLT3/ITD gene has been introduced to express the FLT3/ITD.
- As shown in the working examples, tyrosine-phosphorylation of FLT/ITD was detected in the myeloid cell line, FDC-P1 (ATCC CRL-12103), into which FLT3/ITD was introduced (Example 3). In contrast to the parent cell line FDC-P1, which proliferates IL-3-dependently, FDC-P1 cells into which FLT3/ITD was introduced were found to proliferate IL-3-independently (Example 4). These facts have shown for the first time that tandem duplicate mutation in FLT3 is functionally related to tumorigenesis of blood cells. The inventors have found it possible to inhibit aberrant cell growth and to treat tumors including those found in hematopoietic organs, for example, leukemia, by blocking the FLT3/ITD function as described above.
- One embodiment of the present invention is a method for screening a candidate compound for a drug against tumors, such as blood cancers, using as an index inhibition of the proliferation of animal cells, such as blood cells, in which FLT3/ITD is expressed. Specifically, this method comprises the steps of (a) providing animal cells that proliferate cytokine-independently due to the expression of FLT3/ITD, (b) contacting said cells with a test sample and culturing said cells in the absence of cytokines, (c) detecting the proliferation of said cells, and (d) selecting a compound that inhibits said cell proliferation.
- Another embodiment of the present invention is a method for screening a candidate compound for a drug against tumors, such as blood cancers, using as an index inhibition of tyrosine-phosphorylation of FLT3/ITD in blood cells, etc. Specifically, this method comprises the steps of (a) providing animal cells that proliferates cytokine-independently due to expression of FLT3/ITD, (b) contacting said cells with a test sample and culturing said cells in the absence of cytokines, (c) detecting phosphorylation of FLT3/ITD in said cells, and (d) selecting a compound that inhibits the phosphorylation of FLT3/ITD in said cells.
- Yet another embodiment of the present invention is a method for screening a candidate compound for a drug against tumors, such as blood tumors, using as an index differentiation-inducing potency, i.e. an effect that facilitates cell differentiation, of animal cells, such as blood cells, in which FLT3/ITD is expressed. Specifically, this method comprises the steps of (a) providing animal cells in which differentiation-inducing potency is suppressed due to expression of FLT3/ITD, (b) contacting said cells with a candidate compound and culturing said cells, (c) detecting the differentiation-inducing potency of said cells, and (d) selecting a compound that facilitates differentiation of said cells. Compounds that facilitate cell differentiation include compounds that stimulate the cell differentiation by themselves or together with other cytokines that are known to stimulate the cell differentiation.
- The tumors targeted by drug candidate compounds screened by the method of the present invention include any tumors that are caused by internal tandem duplication (ITD) of FLT3, inter alia, blood cancers, for example, acute myeloid leukemia and myelodysplasia syndrome. In particular, acute myeloid leukemia is the most preferable as a target disease.
- Candidate compounds used in the screening include, but are not limited to, purified proteins (including antibodies), expression products from a gene library, a library of synthetic peptides, cell extracts, cell culture supernatant, a library of synthetic low-molecular-weight compounds, oligonucleotides, etc.
- Any animal cell can be used as the cells used for the screening as long as it proliferates cytokine-independently or has suppressed differentiation-inducing potency due to the FLT3/ITD expression. Blood cells (including hematopoietic stem cells) are preferable. Such cells include, for example, FDC-P1 cells (ATCC: CRL-12103), 32D cells (RICKEN (The Institute of Physical and Chemical Research) Cell Bank: RCB 1145), Ba/F3 cells (RICKEN Cell Bank: RCB 0805), DA-3 cells (RICKEN Cell Bank: RCB 1144), all of which show IL3-independent cell proliferation. Among them, in particular, FDC-P1, 32D, and Ba/F3 cells are preferable. Intracellular expression of FLT3/ITD can be carried out by means of a genetic engineering technique well known to those skilled in the art. Any FLT3/ITD can be used for its expression in the cell, as long as it induces the proliferation of blood cells in a cytokine-independent manner. Such FLT3/ITD includes, for example, FLT3/ITD comprising any one of the amino acid sequences of SEQ ID NO: 2, 4, 6 and 8. The FLT3/ITD sequences described in the literatures (Yokota, S. et al. 1997, Leukemia 11: 1605-1609; Kiyoi, H. et al. 1997, Leukemia 11: 1447-1452) canbeusedinthisinvention. Inaddition, FLT3/ITD newly obtained from patients with blood cancer can also be used. FLT3/ITD may be synthesized artificially or derived from cells.
- Candidate compounds can be contacted with cells by the method suitable to the compounds used, for example, by the method in which a candidate compound is added to the cell culture medium or the method in which a candidate compound is introduced into the cells.
- The followings are specific examples of the screening methods of the present invention, but they are not construed to limit the scope of the present invention.
- (i) Wild type FLT3 or FLT3/ITD is inserted into a commercially available expression vector carrying a selectable marker such as a neomycin resistance gene, and the vector is introduced into cells, such as FDC-P1 and 32D cells, with an apparatus, such as Bio-Rad Gene Pulser Cuvettes (Bio-Rad) . The cells transfected with FLT3/ITD are selected, seeded onto a 24-well plate to approximately 5 x 104 cells, and cultured in a CO2 incubator at 37°C in the presence or absence of a test sample. Two or three days later, viable cells are counted by trypan blue staining, MTT assay, or other assays, to select a compound that inhibits the cell proliferation.
- (ii) Wild type FLT3 or FLT3/ITD is inserted into a commercially available expression vector carrying a selectable marker such as a neomycin resistance gene, and the vector is introduced into cells, such as FDC-P1 and 32D cells, with an apparatus, such as Bio-Rad Gene Pulser Cuvettes (Bio-Rad). The cells transfected with FLT3/ITD are selected and seeded onto a 10-cm plate to approximately 1 x 106 cells. [γ-32P] ATP is added to the plate. The cells are cultured in the presence or absence of a test sample in a CO2 incubator at 37°C. Subsequently, the cell extract is prepared and immunoprecipitated with anti-FLT3 antibody and anti-phosphorylated-tyrosine antibody, followed by electrophoresis and autoradiography to detect the radioisotope incorporated in FLT3/ITD. A compound that inhibits tyrosine-phosphorylation of FLT3 can thus be selected.
- (iii) Approximately 2 x 107 FDC-P1 cells transfected with FLT3/ITD by the method described above in (i) are inoculated subcutaneously to DBA2 mice. FDC-P1 cells were established from this mouse strain. About two weeks after the inoculation, the mice developed tumors. FLT3/ITD expression in the tumors formed was identified in DNA and protein levels (
Fig. 3A and B ). The tumors were developed without any particular treatment, such as irradiation. That is, the cells, including blood cells, which are transfected with FLT3/ITD, can develop tumors by the action of FLT3/ITD when they are inoculated to non-human mammals, such as syngeneic mice. Therefore, a compound that can inhibit the tumorigenesis can be selected by administering a candidate compound percutaneously, intravenously or orally before or after the inoculation of the cells, such as blood cells, which are transfected with FLT3/ITD, and examining their effect on the development and elimination of the tumors. - (iv) The inventors have found that 32D cells, for example, are IL3-dependent cells and their differentiation are induced in the presence of G-CSF, and that the G-CSF-induced differentiation is inhibited when FLT3/ITD is introduced into the cells. On the basis of this knowledge, the following method has been developed. Approximately 5 x 104 cells of the transformed cells, such as blood cells that are transfected with wild type FLT3 or FLT3/ITD by the method described above in (i) are seeded onto a 24-well plate. Cytospin samples are prepared at various time points after adding a candidate compound to examine their potential for differentiation by staining with May-Giemsa, peroxidase, esterase, alkaline phosophatase, etc. or by flow cytometry to determine the expression of CD11b, CD13, CD14 and CD33, etc. A compound that promotes the differentiation-inducing potency of the cells can thus be selected.
- To eliminate the effects of nonselective cytotoxic substances in the screening system in which cell proliferation is used as an index, the parent cells are cultured in the presence of IL-3 and a candidate compound is added to the culture to determine the effects of the candidate compound on IL-3-dependent cell-proliferation in parallel with the experiment above.
- The compounds that can be isolated through the screening of the present invention may vary in their activities. Examples of the compounds include, for example, those inhibiting the function of FLT3/ITD through the direct action thereon, those indirectly inhibiting the FLT3/ITD function by acting on a molecule that binds to FLT3/ITD or phosphorylated FLT3/ITD (e.g. adapter proteins, such as SHC, Grb2, Cbl, PI3K, RAS-GAP and PLC-γ), those acting on a group of proteins that is involved in the signal transduction pathway from FLT/ITD up to cell proliferation, those acting on a protein that can phosphorylate FLT3/ITD and inhibiting the function thereof, those acting on a group of proteins that is involved in the signal transduction pathway from FLT/ITD to cause its phosphorylation, and those dephosphorylating FTL3/ITD that is constitutively phosphorylated.
- These compounds are candidates for a drug to treat tumors, such as blood cancers, in the development which FLT3/ITD is involved. Among the compounds screened, the compounds that specifically inhibit the FLT3/ITD function but not inhibit the function of wild type FLT3 are preferable as candidates for drugs to specifically treat the diseases mentioned above caused by FLT3/ITD.
- The present application further describes that in case a compound is isolated by the screening method of the present invention it may be used as a drug. In this case it is described to be formulated by any pharmaceutical manufacturing methods well known in the art. For example, the drug may be combined with a pharmaceutically acceptable carrier or medium (e.g. saline, vegetable oil, suspending agent, surfactant, stabilizer, etc.) and administered to patients. The drug may be administered via various routes, for example, percutaneously, intranasally, transbronchially, intramuscularly, intravenously, or orally, depending on the properties of the compound. Dosage may vary depending on the factors, such as age, weight, condition of the patient and the administration method, but those skilled in the art can properly determine the suitable dosage.
-
-
Fig. 1 shows tyrosine-phosphorylation of FLT3 protein in FDC-P1 cells into which wild type FLT3 or FLT3/ITD has been introduced. The cell extracts were immunoprecipitated with anti-FLT3 antibody (IP: FLT3), resolved by SDS-PAGE, and subjected to Western blotting with anti-phosphorylated-tyrosine antibody (Upper panel, IB: pTyr). The same membrane was further subjected to Western blotting using anti-FLT3 antibody (Lower Panel, IB:FLT3).Lane 1, Mt1;Lane 2, Mt2;Lane 3, Mt3; andLane 4, Mt4. -
Fig. 2 shows the proliferation properties of FDC-P1 cells into which wild type FLT3 or one of four FLT3/ITD mutants has been introduced. Each mutant was cultured in the absence of IL-3 and FL (Upper left graph, IL3(-)/FL(-)); in the presence of IL-3 (1 ng/ml) (Upper right graph, IL3(1 ng/ml)/FL(-)); in the presence of FL (50 ng/ml) (Lower left graph, IL-3(-)/FL (50 ng/ml)); and in the presence of both IL-3 and FL (Lower right, IL-3 (1 ng/ml)/FL (50 ng/ml)). -
Fig. 3 shows the presence of FLT3/ITD DNA and the expression of its protein in the tumors formed in DBA2 mice that were subcutaneously inoculated with FDC-P1 cells into which FLT3/ITD was introduced. Panel A shows the DNA bands amplified by PCR and resolved by electrophoresis, indicating the presence of FLT3/ITD DNA in the tumors. Panel B shows the results of Western blotting of the whole cell extracts using anti-FLT antibody, indicating the presence of FLT3/ITD protein in the tumors. - The term " aberrant FLT3" refers to any abnormalities of FLT3 including not only expression of mutant to FLT3 but also overexpression of wild type FLT3.
- High molecular weight DNA was isolated from leukemia cells, and a DNA fragment containing the JM domain of the FLT3 protein was amplified by PCR according to the method described in Kiyoi, H., Leukemia 11: 1447-1452, 1997. The bands that differed from the band of the wild-type in size were excised from agarose gel and purified with Qiaex gel extraction kit (Qiagen), followed by cloning into pMOSBlue T vector (Amersham) according to the manufacturer's instruction. Ten colonies of the recombinants were cultured on the LB medium, and the plasmid DNA was prepared with QIAprep spin plasmid miniprep kit (QIAGEN). Nucleotide sequences of these clones were confirmed by sequencing. Expression of the FLT3 mRNA was confirmed by RT-PCR according to the method described in Kiyoi, H., Leukemia 11: 1447-1452, 1997. The bands that differed from the band of the wild type in size were cloned according to the method described above, and their nucleotide sequences were confirmed by sequencing.
- The results are summarized in Table 1 showing the frequency of FLT3/ITD within various blood cancers (the number of cases in which FLT3/ITD was detected/the total number of cases tested).
Table 1 Diagnosis Frequency Diagnosis Frequency ALL 0/48 AML(total) 35/221 ATL 0/14 M0 0/2 CLL 0/15 M1 5/18 ET 0/3 M2 4/29 ML 0/16 M3 16/124 MM 0/38 M4 6/24 Histiocytosis 0/1 M5 4/20 CML- BC 0/13 M6 0/1 CMMoL 0/17 M7 0/3 MDS 1/15 - It was confirmed that among various blood cancers, FLT3/ITD is specifically found in AML; its percent frequency was so high as about 20%. FLT3/ITD was also found in MDS, but its percent frequency was so low as about 3%.
- Example 2. Introduction of an FLT3/ITD expression vector into blood cells
- Total RNA was extracted from leukemia cells and was used for cDNA synthesis. The cDNA synthesized was used as a template to amplify the MunI-EcoRV fragment, which contains the tandem repeat region found in mutants FTL3 cDNA, by RT-PCR. MunI-F primer (SEQ ID NO: 11/5'-CAACAATTGGTGTTTGTCTCCTCTT-3') and EcRV-R primer (SEQ ID NO: 12/5'-CATGATATCTCGAGCCAATCCAAAG-3') were used for the amplification. The amplified fragments were cleaved with MunI and EcoRV (Boehringer-Mannheim-Yamanouchi), resolved on agarose gel, and purified according to the aforementioned method. Expression vector pCDHF3 (a gift from Dr. Olivier Rosnet), which carries a full-length wild type FLT3 cDNA (Rosnet, O. et al., Blood 82:1110-1119; Accession No. S64785), was cleaved with MunI and EcoRV, and the purified FLT3/ITD fragment was inserted into the vector. Four mutants of FLT3/ITD (Mtl, Mt2, Mt3 and Mt4) were used. Nucleotide sequences of the mutated regions of Mt1 to Mt4 are shown as SEQ ID NOs. 1, 3, 5 and 7, and their amino acid sequences are shown as SEQ ID NOs. 2, 4, 6 and 8, respectively. Expression vectors for Mt1 to Mt4 were transfected into the blood cells.
- FLT3/ITD expression plasmids thus obtained were introduced into blood cells as follows. The cells were co-transfected with a 10:1 mixture of any one of the expression plasmids and pBabe-neo vector (Nucleic Acids Res., 18:3587-3596, 1990) by using Bio-Rad Gene Pulser Cuvettes (Bio-Rad; 300 V, 960 µF), and selected with 800 ng/ml neomycin. After cloning, FLT3 expressions of the cloned cells were verified by FACS and Western blotting to establish the transfected clones.
- FLT3/ITD genes were introduced into a myeloid cell line, FDC-P1 cells.
- (1) The transfectants were cultured in RPMI 1640 medium supplemented with 10% FCS (GIBCO), and then centrifuged at 1000 rpm for 5 minutes to recover 2 x 107 cells. The cell pellets were washed with PBS, dissolved in lysis buffer (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 2 mM EDTA, Nonidet P-40, 50 mM NaF, 10 mg/ml aprotinin, 10 mg/ml leupeptin, 1 mM Na3VO4, 50 mM Na2MoO4, 1 mM phenylmethylsulfonyl fluoride (PMSF)), allowed to stand for 1 hour at 4°C, then centrifuged at 15000 rpm for 30 minutes. Rabbit anti-human FLT3 antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) was added to the supernatants and the mixture was stirred for 2 hours at 4°C. After adding Protein A/G Plus agarose (Santa Cruz), the resulting mixture was stirred for 2 hours at 4°C and washed with the lysis buffer three times. The pellets were then dissolved in sample loading buffer (0.125 M Tris-HCl, pH 6.8, 10% 2-mercaptoethanol, 4% SDS), subjected to SDS-PAGE, transferred onto Immobilon PVDF membrane (Millipore), and reacted with anti-phosphorylated tyrosine antibody (4G10, Upstate Biotechnology, Lake Placid, NY, USA). Following the reaction, the bands were detected using the ECL system (Amersham). To confirm the presence of FLT3 protein, the same membrane was incubated in stopping buffer (100 mM 2-mercaptoethanol, 2% SDS, 62.5 mM Tris-HCl, pH 6.8) for 30 minutes at 70°C, and then reacted with rabbit anti-human FLT3 antibody.
- The results for FDC-P1 cells are shown in
Fig. 1 . As shown in this figure, all the FLT3/ITDs introduced into FDC-P1 cells were phosophorylated at the tyrosine residues, indicating that a signaling pathway for tyrosine-phosphorylation of FLT3/ITD is constitutively activated. On the contrary, wild type FLT3 protein was not phosphorylated in the absence of FL. - The same result was obtained for 32D cells.
- FDC-P1 cells (5 x 104 cells) into which wild type FLT3 (wt) or FLT3/ITD (Mt1 to Mt4) was introduced were cultured in the four media indicated below on a 24-well plate at 37°C in a CO2 incubator.
- 1. RPMI1640 supplemented with 10% FCS alone (
Fig. 2 , upper left graph); - 2. RPMI1640 supplemented with 10% FCS + 1 ng/ml mouse IL-3 (Genzyme) (
Fig. 2 , upper right graph); - 3. RPMI1640 supplemented with 10% FCS + 50 ng/ml human FL (Purotech) (
Fig. 2 , lower left graph); - 4. RPMI1640 supplemented with 10% FCS + 1 ng/ml mouse IL-3 + 50 ng/ml human FL (
Fig. 2 . lower right graph). - The cells were stained with trypan blue and the viable cells were counted at 24-hour intervals for 4 days to determine the proliferation potency of each cell line. The results are shown in
Fig. 2 . As shown in the figure, the cells into which wild type FLT3 is introduced were not able to proliferate in the absence of IL-3, and this IL-3 dependency did not alter even after FL, a ligand for FLT3, was added to the medium. Also, synergistic effect of IL-3 and FL was not observed. In contrast, the cells into which FLT3/ITD was introduced proliferated at an equivalent level irrespective of the presence of IL-3, and their proliferation rate was significantly higher than that of the cells into which wild type FLT3 is introduced in the presence IL-3. Also, neither proliferation promoting effect nor synergistic effect of IL-3 and FL were found in these cells. - These data reveal that FLT3/ITD activates intracellular signaling pathways and triggers cytokine-independent proliferation in the myeloid cells.
- The same results were obtained for 32D cells.
- The present invention provides a method for screening candidate compounds for drug against tumors, such as blood cancers, using inhibition of FLT3/ITD function as an index. Compounds to be isolated by the method of the present invention could have an inhibitory effect on aberrant proliferation of cells, such as blood cells, caused by FLT3/ITD expression found in blood cancers, in particular, acute myeloid leukemia, and can thus be utilized for development of pharmaceuticals for these diseases.
-
- <110> CHUGAI SEIYAKU KABUSHIKI KAISHA
- <120> METHOD FOR SCREENING CANDIDATE COMPOUNDS FOR ANTITUMOR DRUG
- <130> F 1248 EP
- <150>
JP 1998-233729
<151> 1998-08-20 - <160> 10
- <170> PatentIn Ver. 2.0
- <210> 1
<211> 319
<212> DNA
<213> Homo sapiens - <220>
<221> CDS
<222> (1)..(318)
<223> FLT3/ITD gene (Mt1); partial sequence - <400> 1
- <210> 2
<211> 106
<212> PRT
<213> Homo sapiens - <220>
<223> FLT3/ITD (Mt1); partial sequence ITD region (42)..(68) - <400> 2
- <210> 3
<211> 298
<212> DNA
<213> Homo sapiens - <220>
<221> CDS
<222> (1)..(297)
<223> FLT3/ITD gene (Mt2); partial sequence - <400> 3
- <210> 4
<211> 99
<212> PRT
<213> Homo sapiens - <220>
<223> FLT3/ITD (Mt2); partial sequence ITD region (35)..(54) - <400> 4
- <210> 5
<211> 271
<212> DNA
<213> Homo sapiens - <220>
<221> CDS
<222> (1)..(270)
<223> FLT3/ITD gene (Mt3); partial sequence - <400> 5
- <210> 6
<211> 90
<212> PRT
<213> Homo sapiens - <220>
<223> FLT3/ITD (Mt3); partial sequence ITD region (31)..(42) - <400> 6
- <210> 7
<211> 271
<212> DNA
<213> Homo sapiens - <220>
<221> CDS
<222> (1)..(270)
<223> FLT3/ITD gene (Mt4); partial sequence - <400> 7
- <210> 8
<211> 90
<212> PRT
<213> Homo sapiens - <220>
<223> FLT3/ITD (Mt4); partial sequence ITD region (30)..(40) - <400> 8
- <210> 9
<211> 25
<212> DNA
<213> Artificial Sequence - <220>
<223> Description of Artificial Sequence:A primer for amplifying human FLT3/ITD genes - <400> 9
caacaattgg tgtttgtctc ctctt 25 - <210> 10
<211> 25
<212> DNA
<213> Artificial Sequence - <220>
<223> Description of Artificial Sequence:A primer for amplifying human FLT3/ITD genes. - <400> 10
catgatatct cgagccaatc caaag
Claims (8)
- A method for screening a candidate compound for an antitumor drug, said method comprising the steps of:(a) providing animal cells which express FLT3/ITD, whereupon said cells proliferate IL-3 independently;(b) contacting said cells with a candidate compound and culturing said cells in the absence of IL-3;(c) detecting the proliferation of said cells; and(d) selecting the candidate compound that inhibits the proliferation of said cells.
- A method for screening a candidate compound for an antitumor drug, said method comprising the steps of:(a) providing animal cells which express FLT3/ITD, whereupon said cells proliferate IL-3 independently;(b) contacting said cells with a candidate compound and culturing said cells in the absence of IL-3;(c) detecting phosphorylation of FLT3/ITD in said cells; and(d) selecting the candidate compound that inhibits the phosphorylation of FLT3/ITD in said cells.
- A method for screening a candidate compound for an antitumor drug, said method comprising the steps of:(a) providing animal cells which express FLT3/ITD, whereupon G-CSF-induced differentiation of said cells is suppressed ;(b) contacting said cells with a candidate compound and culturing said cells in the presence of G-CSF;(c) detecting the differentiation-inducing potency of said cells; and(d) selecting the candidate compound that facilitates differentiation of said cells.
- The method according to any one of claims 1 to 3 , wherein said tumor is a blood cancer.
- The method according to claim 4, wherein said blood cancer is acute myeloid leukemia or myelodysplasia syndrome.
- The method according to any one of claims 1 to 3, wherein said animal cells are animal blood cells.
- The method according to claim 6, wherein said animal blood cells are FDC-P1, 32D, or BaF cells, in which FLT3/ITD gene has been introduced to express the FLT3/ITD.
- The method according to claim 3, wherein said animal cells are 32D cells, in which the FLT3/ITD gene has been introduced to express the FLT3/ITD.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP23372998 | 1998-08-20 | ||
JP23372998 | 1998-08-20 | ||
PCT/JP1999/004450 WO2000011470A1 (en) | 1998-08-20 | 1999-08-19 | Method for screening candidate compounds for drug against tumor |
Publications (3)
Publication Number | Publication Date |
---|---|
EP1109020A1 EP1109020A1 (en) | 2001-06-20 |
EP1109020A4 EP1109020A4 (en) | 2005-01-05 |
EP1109020B1 true EP1109020B1 (en) | 2008-12-24 |
Family
ID=16959668
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP99938521A Expired - Lifetime EP1109020B1 (en) | 1998-08-20 | 1999-08-19 | Method for screening candidate compounds for antitumor drug |
Country Status (7)
Country | Link |
---|---|
US (3) | US7125659B1 (en) |
EP (1) | EP1109020B1 (en) |
JP (1) | JP4542268B2 (en) |
AT (1) | ATE418730T1 (en) |
AU (1) | AU5301499A (en) |
DE (1) | DE69940158D1 (en) |
WO (1) | WO2000011470A1 (en) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002057847A1 (en) * | 2001-01-19 | 2002-07-25 | Oleksandr Obodnikov | Method for individual selection of remedies for a specific patient |
TWI302836B (en) * | 2001-10-30 | 2008-11-11 | Novartis Ag | Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity |
US8138159B2 (en) | 2003-10-09 | 2012-03-20 | Takara Bio Inc. | Composition for inhibiting function of human Flt3 |
EP1682903A2 (en) * | 2003-11-04 | 2006-07-26 | Roche Diagnostics GmbH | Method for distinguishing aml-specific flt3 length mutations from tkd mutations |
US20110275094A1 (en) * | 2008-11-06 | 2011-11-10 | Gunawardane Ruwanthi N | Phosphorylated fms-related tyrosine kinase 3 biomarker assay |
JP2013510860A (en) | 2009-11-12 | 2013-03-28 | ザ、リージェンツ、オブ、ザ、ユニバーシティ、オブ、ミシガン | Spiro-oxindole MDM2 antagonist |
AU2011326395B2 (en) | 2010-11-12 | 2016-01-07 | Ascenta Licensing Corporation | Spiro-oxindole MDM2 antagonists |
WO2012112956A2 (en) * | 2011-02-19 | 2012-08-23 | The Broad Institute, Inc | Compounds and methods for targeting leukemic stem cells |
AU2012253339B2 (en) | 2011-05-11 | 2016-03-31 | Sanofi | Spiro-oxindole MDM2 antagonists |
CN107072995B (en) * | 2014-08-22 | 2020-02-21 | 富士胶片株式会社 | Pharmaceutical composition for treating FLT3 mutation-positive cancer, mutant FLT3 inhibitor and application of same |
KR102041001B1 (en) | 2014-11-12 | 2019-11-06 | 가톨릭대학교 산학협력단 | Method for quantitative analysis of FLT3 gene mutation and kit |
US11307752B2 (en) | 2019-05-06 | 2022-04-19 | Apple Inc. | User configurable task triggers |
KR102559124B1 (en) * | 2022-08-25 | 2023-07-26 | 주식회사 엔젠바이오 | Composition for amplifying FLT3 gene and Uses thereof |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5635388A (en) | 1994-04-04 | 1997-06-03 | Genentech, Inc. | Agonist antibodies against the flk2/flt3 receptor and uses thereof |
US5981483A (en) * | 1994-05-04 | 1999-11-09 | Mount Sinai Hospital Corporation | Compositions comprising modulators of cytokines of the TGF-β superfamily |
DE69727558T2 (en) * | 1996-03-15 | 2004-12-16 | Munin Corporation, Chicago | Human CYR61, a signaling molecule of the extracellular matrix |
EP0816848A1 (en) * | 1996-06-28 | 1998-01-07 | BOEHRINGER INGELHEIM INTERNATIONAL GmbH | Method for comparative screening of substances with pharmacological activity |
PT959132E (en) * | 1996-10-18 | 2006-12-29 | Takara Bio Inc | Nucleic acid encoding receptor type protein kinase |
US6846630B2 (en) * | 1996-10-18 | 2005-01-25 | Takara Shuzo Co., Ltd. | Nucleic acid encoding receptor type protein kinase |
-
1999
- 1999-08-19 US US09/763,175 patent/US7125659B1/en not_active Expired - Fee Related
- 1999-08-19 EP EP99938521A patent/EP1109020B1/en not_active Expired - Lifetime
- 1999-08-19 AU AU53014/99A patent/AU5301499A/en not_active Abandoned
- 1999-08-19 JP JP2000566675A patent/JP4542268B2/en not_active Expired - Fee Related
- 1999-08-19 AT AT99938521T patent/ATE418730T1/en not_active IP Right Cessation
- 1999-08-19 DE DE69940158T patent/DE69940158D1/en not_active Expired - Lifetime
- 1999-08-19 WO PCT/JP1999/004450 patent/WO2000011470A1/en active Application Filing
-
2006
- 2006-09-15 US US11/521,372 patent/US7858333B2/en not_active Expired - Fee Related
-
2010
- 2010-11-12 US US12/926,346 patent/US8426131B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US7858333B2 (en) | 2010-12-28 |
AU5301499A (en) | 2000-03-14 |
US7125659B1 (en) | 2006-10-24 |
DE69940158D1 (en) | 2009-02-05 |
US20070009973A1 (en) | 2007-01-11 |
EP1109020A4 (en) | 2005-01-05 |
US8426131B2 (en) | 2013-04-23 |
ATE418730T1 (en) | 2009-01-15 |
US20110257366A1 (en) | 2011-10-20 |
JP4542268B2 (en) | 2010-09-08 |
EP1109020A1 (en) | 2001-06-20 |
WO2000011470A1 (en) | 2000-03-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7858333B2 (en) | Method for screening candidate compounds for antitumor drug | |
Martin-Zanca et al. | Molecular and biochemical characterization of the human trk proto-oncogene | |
Stirewalt et al. | The role of FLT3 in haematopoietic malignancies | |
EP2502628B1 (en) | Polynucleotides and polypeptide sequences involved in cancer | |
EP2116553B1 (en) | EML4-ALK fusion gene | |
Ardini et al. | Anaplastic Lymphoma Kinase: role in specific tumours, and development of small molecule inhibitors for cancer therapy | |
EP3296407A1 (en) | Mutations of the pik3ca gene in human cancers | |
JP4276432B2 (en) | Method for regulating cell growth by MUC1 | |
JP5554925B2 (en) | Translocation and mutant ROS kinase in human non-small cell lung cancer | |
KR20140057361A (en) | Methods and compositions for the treatment and diagnosis of cancer | |
KR102097859B1 (en) | Biomarkers for predicting the response of anticancer drugs to gastric cancer and their uses | |
CN101532060A (en) | Genes and polypeptides relating to hepatocellular or colorectal carcinoma | |
CA2558813A1 (en) | Pharmaceutical composition comprising cxcr3 inhibitor | |
US20080280288A1 (en) | Assay Method to Predict Sensitivity of Cancer Cell to Anticancer Drug | |
EP2695950A1 (en) | Markers for responsiveness to an inhibitor of the fibroblast growth factor receptor | |
CN111187835A (en) | Pancreatic cancer target ERBB2 and its application in diagnosis and treatment | |
JP5883396B2 (en) | A method for suppressing cancer cell survival promoting signals mediated by receptor tyrosine kinases | |
KR20150085459A (en) | Novel NTRK1 fusion gene as colon cancer marker and the uses thereof | |
KR20160147091A (en) | A method for diagnosing a gastric cancer and a diagnostic kit using the method | |
KR102074559B1 (en) | Biomarker for diagnosis of anticancer drug resistance of gastric cancer and use thereof | |
WO2014017106A1 (en) | Compositions Comprising RAC Mutants, and Methods of Use Thereof | |
Ruzzi et al. | ADK-VR2, a cell line derived from a treatment-naïve patient with SDC4-ROS1 fusion-positive primarily crizotinib-resistant NSCLC: a novel preclinical model for new drug development of ROS1-rearranged NSCLC | |
WO2005038005A9 (en) | Shc proteins as therapeutic targets in proliferative diseases | |
CA2773614A1 (en) | Method of treating cancer by inhibiting trim59 expression or activity | |
US20130345145A1 (en) | Atip3 and biologically active fragments thereof for use in the treatment of cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20010320 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
AX | Request for extension of the european patent |
Free format text: AL;LT;LV;MK;RO;SI |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20041123 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
RTI1 | Title (correction) |
Free format text: METHOD FOR SCREENING CANDIDATE COMPOUNDS FOR ANTITUMOR DRUG |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REF | Corresponds to: |
Ref document number: 69940158 Country of ref document: DE Date of ref document: 20090205 Kind code of ref document: P |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: VOSSIUS & PARTNER |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20081224 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20081224 |
|
NLV1 | Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act | ||
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090404 Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20081224 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090324 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090525 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20081224 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20081224 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20090925 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20090831 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20090819 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090325 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20081224 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20090819 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20081224 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20130813 Year of fee payment: 15 Ref country code: DE Payment date: 20130814 Year of fee payment: 15 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20130808 Year of fee payment: 15 Ref country code: GB Payment date: 20130814 Year of fee payment: 15 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 69940158 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20140819 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140831 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140831 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 69940158 Country of ref document: DE Effective date: 20150303 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20150430 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140819 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150303 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140901 |